Salix Pharmaceuticals, Ltd. news

   Watch this stock
Showing stories 1 - 10 of about 95   

Articles published

SLXP 172.81
price chart
Why Salix Pharmaceuticals, Ltd. Stock Was Clobbered in November
What: Shares of Salix Pharmaceuticals (NASDAQ:SLXP), a biopharmaceutical company that develops and acquires drugs designed to treat gastrointestinal diseases, was clobbered in November and fell by 29%, based on data from S&P Capital IQ, after the ...
Related articles »  
Why Salix Pharmaceuticals Ltd. Stock Was Throttled
What: Salix Pharmaceuticals (NASDAQ:SLXP), a biopharmaceutical company focused on developing and acquiring drugs targeting gastrointestinal diseases, gave its own shareholders indigestion today when the stock plunged as much as 40% on ...
Salix Pharmaceuticals, Ltd. (SLXP) 3Q Earnings Disappoint; Shares Tumble 38 ...  Bidness ETC
Salix Pharmaceuticals profit, revenue miss estimates  Reuters
Related articles »  
Recent Broker Updates On Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP)
Recently stock market analysts have updated their consensus ratings on shares of Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP).
Here's Why Salix Pharmaceuticals, Ltd. Executives Received Millions Even After ...
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) has paid as much as $46 million combined to two of the top executives who left the company following the accounting scandal late last year.
Salix execs – including two that resigned – to receive $78M in golden ...  Triangle Business Journal
Salix Executives Who Left After Financial Errors Get $46 Million  Bloomberg
Why Salix Pharmaceuticals Ltd. Stock Surged
What: Shares of Salix Pharmaceuticals (NASDAQ:SLXP), a globally diversified pharmaceutical company focused primarily on treating gastrointestinal diseases, rocketed higher by as much as 13% after reporting positive late-stage data for rifaximin (known ...
Salix Pharmaceutical: A Good Find In Specialty Pharma (SLXP)  Seeking Alpha
Effect of Medical Studies on Company Stocks of Salix Pharmaceuticals, Ltd ...
Related articles »  
3 Pharma Companies Competing To Acquire Salix Pharmaceuticals, Ltd. : Who Will ...
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP), a Raleigh-based specialty pharmaceutical company focusing on innovative treatments for various gastrointestinal disorders, has been the top potential takeover target for some of the major pharmaceutical ...
Valeant Pharmaceuticals International, Inc. Completes Tender Offer For Salix ...
LAVAL, Quebec, April 1, 2015 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") today announced the expiration of the tender offer (the "Offer") by a subsidiary of Valeant Pharmaceuticals International ...
Valeant Pharma (VRX) Announces Results of $173/Share Salix Pharma (SLXP) Tender
Valeant closes $11B deal for Raleigh's Salix Pharmaceuticals  Triangle Business Journal
Salix Pharmaceuticals, Ltd. Confirms Receipt of an Unsolicited Proposal from ...
RALEIGH, N.C.--(BUSINESS WIRE)--Salix Pharmaceuticals, Ltd. (Nasdaq: SLXP) (“Salix” or the “Company”) today confirmed that it has received an unsolicited proposal from Endo International plc (“Endo”) to acquire all of the outstanding shares of common ...
Endo makes takeover offer for Salix Pharmaceuticals  MarketWatch
Endo International plc - Ordinary Shares Tries To Woo Salix Pharmaceuticals ...  Bidness ETC
Salix Pharmaceuticals, Ltd. (SLXP) Q4 Revenue Hits A Record Low
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) on Monday announced its fourth-quarter financial results for fiscal'14 (4QFY14), registering a hefty decline in revenue as it ceases sales to wholesalers.
Salix Pharmaceuticals Reports 4Q2014 and FY2014 Results  Business Wire (press release)
An Overview of Salix Pharmaceuticals Ltd. (NASDAQ:SLXP) Fourth Quarterly ...
Salix Pharmaceuticals, Ltd. (SLXP) Q1 Earnings Preview: What To Expect
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) is scheduled to announce its financial results for the first quarter of fiscal year 2015 (1QFY15) on Thursday, May 7 after the markets close.